Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01461
|
|||||
| Drug Name |
AG 337
|
|||||
| Synonyms |
Thymitaq; AG-337; ZX-337; Nolatrexed (intravenous), EXIMIAS
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Lung cancer [ICD11: 2C25] | Phase 3 | [1] | |||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C14H14Cl2N4OS
|
|||||
| Canonical SMILES |
CC1=C(C2=C(C=C1)N=C(NC2=O)N)SC3=CC=NC=C3.Cl.Cl
|
|||||
| InChI |
InChI=1S/C14H12N4OS.2ClH/c1-8-2-3-10-11(13(19)18-14(15)17-10)12(8)20-9-4-6-16-7-5-9;;/h2-7H,1H3,(H3,15,17,18,19);2*1H
|
|||||
| InChIKey |
PJKVJJYMWOCLIJ-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 152946-68-4
|
|||||
| Pharmaceutical Properties | Molecular Weight | 357.3 | Topological Polar Surface Area | 106 | ||
| Heavy Atom Count | 22 | Rotatable Bond Count | 2 | |||
| Hydrogen Bond Donor Count | 4 | Hydrogen Bond Acceptor Count | 4 | |||
| PubChem CID | ||||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
| References | ||||||
| 1 | ClinicalTrials.gov (NCT00012324) Nolatrexed Dihydrochloride Compared With Doxorubicin in Treating Patients With Recurrent or Unresectable Liver Cancer | |||||
| 2 | Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolates. Cancer Chemother Pharmacol. 2006 Dec;58(6):826-34. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.